Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose dexamethasone for early hospitalized COVID-19 pneumonia
2021-001416-29Phase 3Active
- Sponsor
- Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Sofía y del Hospital Universitario del Henares
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexamethasone in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Sofía y del Hospital Universitario del Henares. Primary endpoint: Requirement of respiratory therapy with NIV/MIV/OCNAF. Started May 2021; status: active.
02
Drugs
dexamethasone
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on 2021-001416-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001416-29.